Los Angeles Capital Management LLC Buys 1,500 Shares of Translate Bio, Inc. (NASDAQ:TBIO)

Los Angeles Capital Management LLC increased its stake in Translate Bio, Inc. (NASDAQ:TBIO) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,480 shares of the company’s stock after buying an additional 1,500 shares during the period. Los Angeles Capital Management LLC’s holdings in Translate Bio were worth $875,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Arizona State Retirement System raised its stake in Translate Bio by 4.0% in the fourth quarter. Arizona State Retirement System now owns 12,919 shares of the company’s stock worth $238,000 after buying an additional 502 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in Translate Bio by 3.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 25,392 shares of the company’s stock worth $346,000 after buying an additional 740 shares in the last quarter. TFC Financial Management purchased a new stake in Translate Bio in the third quarter worth about $25,000. Pacer Advisors Inc. grew its holdings in Translate Bio by 106.3% in the fourth quarter. Pacer Advisors Inc. now owns 3,640 shares of the company’s stock worth $67,000 after purchasing an additional 1,876 shares during the period. Finally, ProShare Advisors LLC grew its holdings in Translate Bio by 20.0% in the third quarter. ProShare Advisors LLC now owns 20,320 shares of the company’s stock worth $277,000 after purchasing an additional 3,390 shares during the period. 92.90% of the stock is owned by institutional investors.

In related news, Director Jean Francois Formela sold 56,536 shares of the firm’s stock in a transaction that occurred on Monday, December 21st. The shares were sold at an average price of $25.50, for a total value of $1,441,668.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.30% of the company’s stock.

NASDAQ:TBIO opened at $23.42 on Tuesday. The company’s 50 day moving average price is $24.59 and its 200-day moving average price is $18.54. Translate Bio, Inc. has a 52 week low of $6.80 and a 52 week high of $34.64. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -21.89 and a beta of 0.96.

A number of equities research analysts have weighed in on the stock. SVB Leerink upped their price objective on shares of Translate Bio from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Monday, November 9th. Zacks Investment Research cut shares of Translate Bio from a “hold” rating to a “sell” rating in a report on Thursday, February 11th. TheStreet upgraded shares of Translate Bio from a “d+” rating to a “c-” rating in a report on Friday, February 5th. Finally, Roth Capital upped their price objective on shares of Translate Bio from $30.00 to $37.00 in a report on Tuesday, December 22nd. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $30.88.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Read More: What is a capital gain?

Want to see what other hedge funds are holding TBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Translate Bio, Inc. (NASDAQ:TBIO).

Institutional Ownership by Quarter for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.